ClinicalTrials.gov
ClinicalTrials.gov Menu

The Expression of TLR2 and TLR4 in the Lung of Chronic Obstructive Pulmonary Disease (COPD) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01226199
Recruitment Status : Unknown
Verified June 2011 by Seoul National University Bundang Hospital.
Recruitment status was:  Recruiting
First Posted : October 22, 2010
Last Update Posted : June 8, 2011
Sponsor:
Information provided by:
Seoul National University Bundang Hospital

Brief Summary:
Smoking is the most important risk factor of COPD, but only a fourth of smokers had COPD in their life. There are also healthy smokers without evidence of COPD. Investigators hypothesize that innate immunity may affect this difference between COPD patients and healthy smokers, because TLR4 is the receptor of LPS, which is the one of important substance in cigarette. Investigators will measure TLR2 and TLR4 expression in lung tissue of patients whose lung will be resected. Investigators will compare the level of expression between COPD patients and healthy smokers.

Condition or disease
Smoking COPD

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Expression of TLR2 and TLR4 in the Lung of COPD Patients
Study Start Date : October 2010
Estimated Primary Completion Date : December 2011
Estimated Study Completion Date : March 2012



Biospecimen Retention:   Samples Without DNA
Lung tissues are retained till the study ends.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All patients who will have lung resection for the therapeutic cause.
Criteria

Inclusion Criteria:

  • All patients who will have lung resection for the therapeutic cause.

Exclusion Criteria:

  • Patients who do not agree with our study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01226199


Contacts
Contact: Sei Won Lee, MD 82 31 787 7053 seiwon@snubh.org

Locations
Korea, Republic of
Seoul National University Bundang Hospital Recruiting
Seongnam, Gyeongi, Korea, Republic of, 482 060
Contact: Sei Won Lee, MD    82 31 787 7053    seiwon@snubh.org   
Principal Investigator: Sei Won Lee, MD         
Sponsors and Collaborators
Seoul National University Bundang Hospital

Responsible Party: Sei Won Lee/ Assistant Professor, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT01226199     History of Changes
Other Study ID Numbers: TLR2 and TLR4 in COPD tissue
First Posted: October 22, 2010    Key Record Dates
Last Update Posted: June 8, 2011
Last Verified: June 2011

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases